“It has been over a year of constant trauma. It has been over a year of not sleeping.” How are healthcare workers managing their mental health during the COVID-19 pandemic?
The researchers conducted genome-wide association studies of PTSD in military veterans to explore the genetic association with the common comorbidities of depression and anxiety.
Retrospective study of more than 32,000 veterans sought to determine the incidence, management, and mortality of men with prostate cancer who experience depression.
In an interview with Christine Moutier, MD, psychiatrist and chief medical officer of the American Foundation for Suicide Prevention, she speaks about how the current COVID-19 pandemic presents opportunities to improve suicide prevention efforts on multiple levels.
Researchers conducted a population-based, longitudinal cohort study of data from adolescent participants in the IMAGEN Study, seeking to identify early associations with the development of eating disorders.
Researchers compared the rate at which patients diagnosed with both depression and a substance use disorder received acute and continuous pharmacotherapy and psychotherapy with the rate at which patients solely diagnosed with depression received the same treatments.
This clinical review assessed the use of exposure and response prevention therapy for patients with obsessive-compulsive disorder during the COVID-19 pandemic.
Excessive stress because of the COVID-19 pandemic can have a detrimental effect on nurses’ mental health; therefore, the APNA has developed a Well-Being Initiative for nurses seeking help for excessive stress.
Adherence to antidepressants, rather than the adequacy of the prescribed antidepressant dosage, is predictive of treatment response in middle-aged and older patients who are being treated for depression in primary care.
Researchers assessed data from short-term studies with open-label extensions among adults and adolescents with bipolar depression to assess the impact of lurasidone on treatment-emergent mania.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.